ANRO•benzinga•
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal
Summary
Alto Neuroscience acquires Chase's treatment-resistant depression drug portfolio for $1.75 million upfront; early data shows strong efficacy for lead candidate ALTO-207.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 3, 2025 by benzinga